A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategies
- 16 August 2017
- journal article
- Published by Elsevier BV in Regulatory Toxicology and Pharmacology
- Vol. 90, 22-28
- https://doi.org/10.1016/j.yrtph.2017.08.008
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Is Avoidance of Genotoxic Intermediates/Impurities Tenable for Complex, Multistep Syntheses?Organic Process Research & Development, 2015
- Establishing best practise in the application of expert review of mutagenicity under ICH M7Regulatory Toxicology and Pharmacology, 2015
- A Generic Industry Approach To Demonstrate Efficient Purification of Potential Mutagenic Impurities in the Synthesis of Drug SubstancesOrganic Process Research & Development, 2015
- Mutagenic Impurities: Precompetitive/Competitive Collaborative and Data Sharing InitiativesOrganic Process Research & Development, 2015
- Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impuritiesRegulatory Toxicology and Pharmacology, 2013
- Assessment of Predictivity of Semiquantitative Risk Assessment Tool: Pazopanib Hydrochloride Genotoxic ImpuritiesOrganic Process Research & Development, 2013
- In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry surveyRegulatory Toxicology and Pharmacology, 2012
- Risk Assessment of Potentially Genotoxic Impurities within the Framework of Quality by DesignOrganic Process Research & Development, 2010
- Approaches to Assessment, Testing Decisions, and Analytical Determination of Genotoxic Impurities in Drug SubstancesOrganic Process Research & Development, 2008
- A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicityRegulatory Toxicology and Pharmacology, 2006